 Home > Active Ingredient News > Blood System > J Clin Oncol: The efficacy of ibrutinib combined with rituximab in the first-line treatment of elderly patients with mantle cell lymphoma

J Clin Oncol: The efficacy of ibrutinib combined with rituximab in the first-line treatment of elderly patients with mantle cell lymphoma

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

single source paint

ir impact

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Most patients with mantle cell lymphoma (MCL) are older, with a median age of 69-71 years
.

In addition to the characteristics of high-risk diseases, advanced age, poor performance status, and number of concurrent diseases all have a negative impact on the prognosis of MCL patients

Lymphoma

This is a single-center, single-arm phase 2 clinical trial to study the effectiveness and effectiveness of ibrutinib and rituximab (IR) in the treatment of previously untreated elderly MCL patients (≥65 years of age) Security
.

Elderly MCL patients with Ki-67<50% and non-embryonic cell morphology were recruited, treated with ibrutinib combined with rituximab for two years, and then maintained with ibrutinib alone
.

The primary endpoint is to assess the overall response rate and the safety of the combined regimen

Progression-free survival

A total of 50 MCL patients were recruited, with a median age of 71 years (interquartile range 69-76 years)
.

16% of patients have a high-risk simplified MCL international prognostic index

Overall survival

The best overall response rate was 96% (71% complete response)
.

After a median follow-up of 45 months (interquartile range 24-56 months), 28 (56%) patients dropped out of the study for various reasons (4 cases of progression, 21 cases of toxicity, and 3 cases of other causes)

The best overall response rate was 96% (71% complete response).

Adverse reactions

It is worth noting that 11 patients (22%) developed grade 3 atrial fibrillation
.

Less than 5% of patients have grade 3-4 bone marrow suppression

Eleven (22%) patients developed grade 3 atrial fibrillation

The combination of ibrutinib and rituximab can effectively treat elderly patients with MCL

Original source:

Preetesh Jain, et al.

Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

4-(Aminomethyl)benzoic acid

CAS No.: 56-91-7

$1/KG EXW

GUANFACINE HCL Factory Price Pharmaceutical Chemical Purity Degree 99%

CAS No.: 29110-48-3

Pharmacy Grade

$10-13/G FOB

Hot Selling Powder Flibanserin for for Women CAS 167933-07-5

CAS No.: 167933-07-5

Pharmacy Grade

$5-5.2/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.